Financial Performance - Total revenue for 2025 was RMB 747,645 thousand, a decrease of 32% year-on-year, with product sales revenue at RMB 487,769 thousand, down 44% due to increased market competition [4]. - The company reported revenue of RMB 747,645 thousand for the year ending December 31, 2025, a decrease of approximately 31.9% compared to RMB 1,098,329 thousand in 2024 [16]. - The group reported revenue of RMB 747,645 thousand for the year ended December 31, 2025, a decrease of 31.9% from RMB 1,098,329 thousand in 2024 [31]. - The company reported an operating loss of RMB 90,693 thousand in 2025, compared to an operating profit of RMB 41,254 thousand in 2024 [16]. - The total comprehensive loss for the year was RMB 101,755 thousand in 2025, compared to a comprehensive income of RMB 36,956 thousand in 2024 [16]. - The group incurred a loss attributable to equity holders of RMB (100,369) thousand for the year ended December 31, 2025, compared to a profit of RMB 34,757 thousand in 2024 [39]. - The net loss for 2025 was RMB 100,369 thousand, compared to a net profit of RMB 34,757 thousand in 2024 [53]. - The basic loss per share for the year was RMB (0.14), a decrease from RMB 0.05 in the previous year [17]. Revenue Breakdown - Revenue from product sales was RMB 487,769 thousand in 2025, down 44.4% from RMB 877,410 thousand in 2024 [31]. - CDMO/CMO revenue for the year was RMB 234,939 thousand, an increase of 36.5% compared to RMB 207,133 thousand in 2024 [31]. - CDMO business revenue reached RMB 234,939 thousand, representing a 13% increase year-on-year, highlighting the strategic transformation's success [4]. - The company has maintained a compound annual growth rate of 34% in its CDMO business since its transformation in 2021, demonstrating robust growth momentum [8]. Project Development - The company launched 60 new projects in 2025, bringing the total to 213 projects, with ADC-related projects accounting for 68% of the total [4]. - The total number of projects increased from 153 at the end of 2024 to 213 by the end of 2025, with 60 new projects added during the reporting period [75]. - The company has successfully commercialized its first ADC project, demonstrating its capability in later-stage commercialization projects [77]. - The company secured a Pre-BLA project, increasing the total to 8, which locks in potential future revenue [4]. Quality and Compliance - The company achieved a 100% pass rate in 37 GMP inspections/audits conducted in 2025, including checks from Chinese regulatory authorities and EU QP audits [6]. - The company received GMP certification for its first global EGFR-targeted ADC drug, marking a significant milestone in its quality management system [103]. - The company officially obtained ISO 9001:2015 quality management system certification on January 20, 2026, indicating compliance with international standards [103]. - The quality management system (QMS) was officially launched on February 2, 2026, enhancing the efficiency and compliance level of quality management processes [104]. Financial Position - Total assets decreased to RMB 1,259,289 thousand in 2025 from RMB 1,508,772 thousand in 2024, representing a decline of approximately 16.5% [18]. - Total liabilities decreased to RMB 633,474 thousand in 2025 from RMB 779,117 thousand in 2024, a reduction of about 18.7% [19]. - Non-current assets decreased to RMB 698,373 thousand in 2025 from RMB 765,495 thousand in 2024, reflecting a decline of approximately 8.8% [18]. - Current assets decreased to RMB 560,916 thousand in 2025 from RMB 743,277 thousand in 2024, a decrease of about 24.5% [18]. - The company’s cash and cash equivalents were RMB 327,555 thousand in 2025, down from RMB 381,256 thousand in 2024, a decline of approximately 14.1% [18]. - The company’s total equity decreased to RMB 625,815 thousand in 2025 from RMB 729,655 thousand in 2024, a decrease of about 14.2% [19]. Strategic Initiatives - A strategic merger with WuXi AppTec is set to enhance the company's comprehensive service capabilities and global market competitiveness, with the transaction expected to complete in the first half of 2026 [13]. - The company aims to build an international operational system leveraging WuXi AppTec's brand and platform advantages to expand both domestic and international markets [14]. - The company plans to enhance its CDMO business by increasing R&D investment and focusing on cutting-edge technologies and key breakthroughs [14]. - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value [146]. Market Trends - The global pharmaceutical R&D investment reached $241.5 billion in 2022, with an outsourcing rate of 46.5% [78]. - The global CDMO market size grew from $44.6 billion in 2018 to $79.7 billion in 2023, with a CAGR of 12.3% [82]. - The ADC outsourcing service market size reached $2 billion in 2023, expected to grow to $11 billion by 2030, representing a 450% increase [78]. - The Chinese CDMO market size increased from 16 billion RMB in 2018 to 85.9 billion RMB in 2023, with a CAGR of 39.9% [80]. Employee and Operational Insights - As of December 31, 2025, the company had 613 employees, with 538 in the CDMO team, representing 88% of the total workforce [106]. - The CDMO team has over 76% of its members holding bachelor's degrees or higher, with 71% of personnel in cutting-edge technology fields holding master's or doctoral degrees [106]. - The company has strengthened its CDMO capabilities through technical upgrades, enhancing production flexibility and workshop utilization rates [117]. Awards and Recognition - The company received multiple industry awards, including "Top 10 ESG Competitiveness of Chinese Pharmaceutical Listed Companies" and "Biologics CDMO of the Year" in 2025 [107]. - In November 2025, Dongyao Pharmaceuticals received the "Biologics CDMO of the Year" award at the Biologics CDMO Europe 2025 conference, reinforcing its international brand image as a strategic partner in the biopharmaceutical industry [129]. Future Outlook - The company aims to deepen its strategic transformation by focusing on CDMO/CMO business, which will open up significant international opportunities despite short-term challenges [136]. - The strategic integration with WuXi AppTec is expected to lead to a new phase of resource consolidation and enhanced operational synergy [137]. - The company is actively exploring strategies for global expansion and collaboration in the biopharmaceutical sector, addressing industry challenges and quality issues [126].
东曜药业-B(01875) - 2025 - 年度业绩